Galderma Korea to launch ‘Restylane Eyelight’ in June

Galderma Korea said Friday that it will launch “Restylane Eyelight,” a new product of its premium hyaluronic acid filler brand Restylane, in June in Korea.

Restylane Eyelight features Galderma's proprietary “NASHA” technology, a patented process that enables precise treatment of difficult facial areas with high strength and low deformation. In addition, there is little swelling and no downtime after treatment so that patients can resume their daily activities immediately after treatment.

Restylane Eyelight has won approval from the Ministry of Food and Drug Safety for treating facial wrinkles in adults and will be launched in Korea in June for the first time in the Asia-Pacific region. In clinical trials overseas, 82.9 percent of subjects treated with Restylane Eyelight were either very satisfied or satisfied with the treatment's results, thanks to clinically significant improvement.

"It is very important to choose a product that allows for precise treatment in areas of the face where the skin is thinner and less elastic,” said Lee Jai-hyuck, aesthetics business unit director at Galderma Korea. “Restylane Eyelight, based on Galderma's proprietary NASHA process, will be an innovative product for consumers looking for a natural wrinkle reduction effect."

Lee added that with the launch of Restylane Eyelight, Galderma Korea will continue to strengthen the Restylane brand and lead the latest aesthetic trends to provide consumers with safer and more effective customized treatments.